A recent study suggests that individuals who come off popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt traditional lifestyle programs.
Published data in a major medical journal points out that while obese individuals frequently drop a large proportion of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users buying such drugs need to be informed of the danger of rapid rebound weight gain when the medication concludes," warns researcher Dr. Susan Jebb.
That rate of regain implies a reversion to original mass within about 18 months.
Comparing Approaches
The analysis, which looked at 37 of studies involving thousands of patients, compared the outcomes of these new drugs with other pills.
Researchers point out that people who lose weight through diet and exercise typically see a less rapid creep back—around 100 grams monthly—post-intervention.
Understanding the Quick Rebound
Nutrition scientists believe the mode of action of the jabs accounts for the amplified rebound.
The injections imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than the body's typical production may cause the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating far more likely."
A Chronic Disease?
Medical guidelines advise the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts argue that, due to the high risk of relapse, the therapy is often long-term.
This opinion is echoed by drug manufacturers, who state that the results "highlight the persistent nature of obesity," comparing it to managing diseases like hypertension.
User Accounts
Individuals who have come off the jabs explain a sudden resurgence of hunger.
"I experienced a trigger that goes on and you're instantly extremely hungry," said an individual.
This challenge is compounded if individuals have not adopted permanent lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates suggest that a significant number of people in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers stress that while these medications are potent agents for weight loss, they are not a standalone solution and maintained weight loss likely depends on ongoing lifestyle management.
